66,998 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets bought a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 66,998 shares of the company's stock, valued at approximately $1,578,000. BNP Paribas Financial Markets owned 0.07% of Dyne Therapeutics as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Norges Bank bought a new position in shares of Dyne Therapeutics during the 4th quarter worth about $22,384,000. Springhill Fund Asset Management HK Co Ltd bought a new position in shares of Dyne Therapeutics in the 4th quarter worth $3,091,000. Barclays PLC lifted its stake in shares of Dyne Therapeutics by 162.2% in the third quarter. Barclays PLC now owns 207,309 shares of the company's stock valued at $7,446,000 after buying an additional 128,246 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Dyne Therapeutics during the fourth quarter valued at about $2,340,000. Finally, Trexquant Investment LP grew its holdings in shares of Dyne Therapeutics by 95.6% during the fourth quarter. Trexquant Investment LP now owns 125,378 shares of the company's stock valued at $2,954,000 after buying an additional 61,288 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Stock Down 2.4%

DYN traded down $0.29 during trading on Friday, hitting $11.61. 813,214 shares of the company traded hands, compared to its average volume of 1,639,017. Dyne Therapeutics, Inc. has a one year low of $6.36 and a one year high of $47.45. The stock's fifty day moving average is $10.34 and its 200 day moving average is $17.04. The firm has a market cap of $1.32 billion, a P/E ratio of -3.26 and a beta of 1.19.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). On average, equities research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on DYN. Scotiabank began coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price target on the stock. Piper Sandler cut their target price on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. HC Wainwright decreased their price target on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a report on Friday, May 9th. Guggenheim restated a "buy" rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $47.25.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.